Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Income from Continuing Operations (2019 - 2025)

Goldenwell Biotech's Income from Continuing Operations history spans 7 years, with the latest figure at 7985.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 65.38% year-over-year to 7985.0; the TTM value through Sep 2025 reached 20383.0, up 116.33%, while the annual FY2024 figure was 131498.0, 12.05% down from the prior year.
  • Income from Continuing Operations reached 7985.0 in Q3 2025 per GWLL's latest filing, down from 5220.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 67965.0 in Q4 2024 to a low of 920332.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 68627.53, with a median of 27084.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 16234.25% in 2021, then soared 426.77% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 29554.0 in 2021, then plummeted by 3014.07% to 920332.0 in 2022, then skyrocketed by 97.74% to 20799.0 in 2023, then skyrocketed by 426.77% to 67965.0 in 2024, then crashed by 111.75% to 7985.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Income from Continuing Operations are 7985.0 (Q3 2025), 5220.0 (Q2 2025), and 34377.0 (Q1 2025).